The Cancer Informatics Shared Resource exists to provide infrastructure and expertise that enable Cancer Center members and activities to adopt and deploy good information practices. These low-profile but crucial resources serve to integrate and responsibly curate Cancer Center information throughout the enterprise. Data integrity, consistency, comparability, and interoperability are thereby enhanced. Data-dependent activities and services throughout the Cancer Center are rendered more efficient and reliable as a consequence. The Resource is divided into four teams and an administrative unit. The four teams are: 1) The Cancer Database and Registry (CDR) Team which provides data design, data harvesting, and data integration of all pertinent cancer information for all cancer patients within the Mayo enterprise. The CDR resource serves as the heart of Cancer Center informatics operations, services, data design, and integration. It serves by design as the core for study and disease-specific database extensions. 2) The Study and Disease Databases Team was created to exploit our investment in the CDR and fashion database extensions atop the core database, without duplicating core content. This team also engages in the design and deployment of data access methods relevant to cancer investigators that are latent in the Mayo-IBM Life Sciences Warehouse project, a major partnership between Mayo and IBM which intends to systematically harvest, organize, and responsibly deliver patient data - from genotype to phenotype. 3) The Bioinformatics Team has been assembled from multiple resources to assist Mayo cancer investigators in the use of bioinformatics tools to pinpoint the genetic roots of cancer. Services include the installation and maintenance of genomic analysis software and their associated databases on shared hardware platforms that locally support the computationally intensive requirements of the Cancer Center. And 4) the Informatics Infrastructure Team comprises a multidisciplinary cadre of investigators who contribute importantly to achieving clinical and genomic data that are comparable, interoperable, and consistent. Examples of such infrastructure services include the integration and support of standard terminologies and data structures, the invocation of Metadata for query and data navigation, and the normalization of clinical data harvested from multiple clinical domains and physical locations into comparable and consistent data elements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6989997
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$1
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320

Showing the most recent 10 out of 1129 publications